<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556424</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0056</org_study_id>
    <nct_id>NCT02556424</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema</brief_title>
  <acronym>TRIOZ</acronym>
  <official_title>Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroids, whether injected peri- or intra-ocularly, remain indispensable tools of the
      therapeutic arsenal in treating inflammatory macular edema. However, a few years ago, only
      triamcinolone acetonide was available to ophthalmologists. This molecule, developed initially
      for rheumatological or dermatological use, has been increasingly deployed in ophthalmology,
      while still off-label.

      In 2011, the delivery system of dexamethasone from biodegradable and injectable implant into
      the vitreous cavity obtained the label for inflammatory macular edema. This protocol is
      therefore designed to compare the efficacy and safety of peri- and intra-ocular injections of
      corticosteroids in the treatment of inflammatory macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research compares the implantation techniques of corticosteroids in the eye, with two
      groups of equal size being followed. This is a multi-center, controlled study, with the
      reference drug being the intravitreal implant of 700μg of dexamethasone (Ozurdex®) compared
      to subconjunctival injection of triamcinolone (Kénacort retard®). This is an open,
      prospective, randomized study. It is not possible, for technical reasons, to inject blind two
      products with different injection routes and that are visible to the investigator during
      control examinations (sub-conjunctival crystals and intravitreal implant). However, the
      assessment of visual acuity and central macular thickness will be performed by an uninformed
      ophthalmologist.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the effectiveness of a subconjunctival injection of triamcinolone on reducing the central macular thickness versus an intravitreal implant of dexamethasone between patient selection and 2 months after treatment</measure>
    <time_frame>At 2 months after treatment</time_frame>
    <description>Difference of the central macular thickness in the treated eye, measured by Optical Coherence Tomography (OCT) spectral domain, for each patient between patient selection and 2 months after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the experience of the injection by a questionnaire (tolerable, unpleasant and very unpleasant) and by EVA (0 cm = no pain to 10 cm = extreme pain)</measure>
    <time_frame>At day 0 (= the day of the treatment)</time_frame>
    <description>Scale of &quot;patient experience&quot; the day of the injection (tolerable, unpleasant, very unpleasant) and visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding gain in visual acuity (ETDRS)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Visual acuity (ETDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding reduction of the anterior flare</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Anterior flare (&quot;Lampe A Fente&quot; and Laser Flare Meter, if available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding reduction of the vitreous haze</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Vitreous flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding central macular thickness measured by OCT, allowing the evaluation of the duration of action of the treatment</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Central macular thickness of the eye treated for determining the duration of action</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding local and general tolerance, by collecting all Adverse Events (AEs) / Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluation of tolerance by collecting all AEs / SAEs of randomized patients, such as intra-ocular hypertension, cataracts, endophthalmitis, poor glycemic and/or blood pressure control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding patients' quality of life</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Patients' quality of life questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Inflammatory Macular Edema</condition>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal implant of 700μg of dexamethasone (Ozurdex®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tested Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravitreal implant at D0</description>
    <arm_group_label>Reference Drug</arm_group_label>
    <other_name>Ozurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Subconjunctival injection at 4 mm from the limbus at 6 o'clock</description>
    <arm_group_label>Tested Drug</arm_group_label>
    <other_name>Kénacort retard®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient, male or female (under effective contraception if premenopausal) over 18 years
             old

          -  Patient affiliated with a social security plan

          -  Patient able to understand and follow the instructions of the study

          -  Patient having signed an informed consent

          -  Patient having a central macular thickness greater than 320μm (Spectral Domain, 270µm
             Time Domain)

          -  Patient with an inflammatory macular edema, unilateral or bilateral (in the case of a
             bilateral inflammatory macular edema, the eye most affected will be treated)

        Exclusion Criteria:

          -  Patient with an infectious uveitis

          -  Patient with uncontrolled active infection

          -  Patient receiving an unbalanced general anti-inflammatory and/or immunosuppressive
             and/or immunomodulatory therapy (recent modification &lt;1 month)

          -  Patient having a history of glaucoma and/or ocular hypertension in the eye studied
             (intraocular pressure (IOP) &gt; 25 mmHg without antiglaucoma medication or &gt; 21 mmHg
             with antiglaucoma combination therapy) and/or cortisone-causing-hypertension not
             controlled by an antiglaucoma dual therapy

          -  Patient with uncontrolled diabetes (HbA1c&gt; 8%) or unbalanced hypertension (Systolic
             Blood Pressure &gt; 160 mmHg and/or Diastolic Blood Pressure &gt; 100mmHg)

          -  Edematous diabetic maculopathy

          -  Patient who had received triamcinolone (subconjunctivally or sub-tenon) 3 months
             before randomization, or 700μg dexamethasone intravitreally 6 months before
             randomization

          -  Suspected or active ocular or periocular infection, including most viral diseases of
             the cornea and conjunctiva, such as active epithelial keratitis with herpes simplex
             (dendritic keratitis), vaccinia, varicella, mycobacterial infections and mycoses

          -  History of ocular herpes infection or central serous chorioretinopathy

          -  Aphakic eye with rupture of the posterior lens capsule

          -  Eye with implant in the anterior chamber, iris- or transscleral-fixated intraocular
             implant and rupture of the posterior lens capsule

          -  Uncontrolled systemic inflammatory disease.

          -  Known hypersensitivity to the active substance or to one of the excipients of
             Ozurdex®, Kenacort® or injectable fluorescein

          -  Pregnant woman or likely to become pregnant or nursing

          -  Patient participating in another clinical trial

          -  Adult under a legal protection regime (guardianship, trusteeship, &quot;sauvegarde de
             justice&quot;)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weber Michel, MD</last_name>
    <phone>(0)2 40 48 34 06</phone>
    <phone_ext>+33</phone_ext>
    <email>michel.weber@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Couret Chloé, MD</last_name>
    <email>chloe.couret@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Bénédicte Rougier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Cochard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Creuzot-Garcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Chiquet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre (AP-HP)</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Labetoulle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Labalette, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Kodjikian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Mura, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Weber, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Chloé Couret, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Baillif, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié-Salpêtrière (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bahram Bodaghi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Cochereau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Hélène Errera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Laure Le Lez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Angioi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ophthalmology</keyword>
  <keyword>Uveitic macular edema</keyword>
  <keyword>Triamcinolone subconjunctival injection</keyword>
  <keyword>Dexamethasone intraocular implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

